检索结果-南通市图书馆

Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients

引用

Chinese Medical Journal 2011年第20期124卷 3275-3280页

作者： LI Wei-ming YANG Xin-chun WANG Le-feng GE Yong-gui WANG Hong-shi XU Li NI Zhu-hua ZHANG Da-peng The Heart Center Beijing Chao Yang Hospital Capital MedicalUniversity Beijing 100020 China

Background Primary percutaneous coronary intervention （PCI） is the best treatment of choice for acute ST segment elevation myocardial infarction （STEMI）. This study aimed to determine the clinical outcomes of tirofiban combined with the low molecular weight heparin （LMWH）, dalteparin, in primary PCI patients with acute STEMI. Methods From February 2006 to July 2006, a total of 120 patients with STEMI treated with primary PCI were randomised to 2 groups： unfractionated heparin （UFH） with tirofiban （group I： 60 patients, （61.2±9.5） years）, and dalteparin with tirofiban （group il： 60 patients, （60.5±10.1） years）. Major adverse cardiac events （MACE） during hospitalization and at 4 years after PCI were examined. Bleeding complications during hospitalization were also examined. Results There were no significant differences in sex, mean age, risk factors, past history, inflammatory marker, or echocardiography between the 2 groups. In terms of the target vessel and vascular complexity, there were no significant differences between the 2 groups. During the first 7 days, emergent revascularization occurred only in 1 patient （1.7%） in group I. acute myocardial infarction （AMI） occurred in 1 （1.7%） patient in group I and in 1 （1.7%） in group II. Three （5.0%） patients in group I and 1 （1.7%） in group II died. Total in-hospital MACE during the first 7 days was 4 （6.7%） in group I and 2 （3.3%） in group Ⅱ. Bleeding complications were observed in 10 patients （16.7%） in group I and in 4 patients （6.7%） in group II, however, the difference was not statistically significant. No significant intracranial bleeding was observed in either group. Four years after PCI, death occurred in 5 （8.3%） patients in group I and in 4 （6.7%） in group Ⅱ. MACE occurred in 12 （20.0%） patients in group I and in 10 （16,7%） patients in group Ⅱ. Conclusions Dalteparin was effective and safe in primary PCI of STEMI patients and combined dalteparin with tirofiban was effective and safe without significant bleeding complications compared with UFH. Although the

关键词： acute myocardial infarction, heparin primary percutaneous coronary intervention

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：